Relay Therapeutics, Inc. - Common Stock, par value $0.0001 per share (RLAY)

Historical Holders from Q3 2020 to Q3 2025

Symbol
RLAY on Nasdaq
CUSIP
75943R102
Type / Class
Equity / Common Stock, par value $0.0001 per share
Shares outstanding
171M
All holders as of June 30, 2025
Q2 2025
Total 13F shares, excl. options
171M
Holdings value
$592M
% of all portfolios
0.001%
Grand Portfolio weight change
+0%
Number of holders
204
Number of buys
105
Number of sells
-87
Average Value change %
+0%
Average buys %
+0.001%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Relay Therapeutics, Inc. - Common Stock, par value $0.0001 per share (RLAY)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Point72 Asset Management, L.P. 7.8% +35% $47.5M $13.2M 13.4M +38.7% Point72 Asset Management, L.P. Jun 30, 2025
Commodore Capital LP 7.8% +33.3% $47.1M $11.8M 13.4M +33.5% Commodore Capital LP Jun 30, 2025
BlackRock, Inc. 6.1% -30% $24.9M -$10.6M 10.3M -29.8% BlackRock, Inc. Mar 31, 2025
VANGUARD GROUP INC 5.47% -23.9% $27.7M -$8.04M 9.38M -22.5% The Vanguard Group Jun 30, 2025

Institutional Holders of Relay Therapeutics, Inc. - Common Stock, par value $0.0001 per share (RLAY)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 433K $2.26M +$1.25M $5.22 2
2025 Q2 171M $592M +$36.2M $3.46 204
2025 Q1 163M $426M -$16.3M $2.62 205
2024 Q4 164M $675M -$17.9M $4.12 196
2024 Q3 157M $1.11B +$213M $7.08 192
2024 Q2 127M $826M -$18.8M $6.52 171
2024 Q1 129M $1.07B -$15.2M $8.30 180
2023 Q4 60.6K $675K -$1.94M $11.17 2
2023 Q3 129M $1.08B -$1.94M $8.41 167
2023 Q2 128M $1.6B -$46.6M $12.56 157
2023 Q1 131M $2.15B +$54.4M $16.47 151
2022 Q4 128M $1.91B +$47.8M $14.94 158
2022 Q3 123M $2.76B +$23.7M $22.37 149
2022 Q2 121M $2.02B +$125M $16.75 133
2022 Q1 113M $3.38B +$65.3M $29.93 130
2021 Q4 110M $3.39B +$590M $30.71 126
2021 Q3 91.2M $2.88B +$72.5M $31.53 130
2021 Q2 88.6M $3.24B +$135M $36.59 121
2021 Q1 85.5M $2.95B -$171M $34.57 132
2020 Q4 87.3M $3.63B -$127M $41.56 111
2020 Q3 84.6M $3.6B +$3.6B $42.59 93